Investigational Drug Treatments for Triple-Negative Breast Cancer

Journal of Personalized Medicine

Nikolaos Trakas¹  Vasiliki E. Georgakopoulou²  Afroditi Nonni³  Anna Garmpi⁴  Dimitrios Schizas⁵  Athanasios Syllaios⁵  Evangelos Koustas⁶  Michalis V. Karamouzis⁶  Panagiotis Sarantis⁶  Konstantinos Nikolettos⁷  Konstantinos Kontzoglou⁷  Alexandros Patsouras⁷  Errika Voutyritsa⁷  Efstathios A. Antoniou⁷  Nikolaos Garmpis⁷  Nikos Nikolettos⁸  Christos Damaskos⁹  Dimitrios Dimitroulis^1,10 

[1] Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece;Department of Pulmonology, Laiko General Hospital, 11527 Athens, Greece;First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;First Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;Obstetric-Gynecologic Clinic, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece;Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece;Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;

关键词: novel therapeutic strategies;    immunotherapy;    targeted therapies;    PI3kb/mTOR inhibitors;    PARP inhibitors;    histone deacetylase inhibitors;   

DOI  :  10.3390/jpm11070652

来源: DOAJ

【 摘 要 】

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which constitutes the most often recommended treatment. New beneficial targeted therapies are important to be investigated in order to achieve enhanced outcomes in patients with TNBC. This review will focus on recent therapeutic innovations for TNBC, focusing on various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase inhibitors, histone deacetylase inhibitors (HDACIs), and immune checkpoint inhibitors.

【 授权许可】

Unknown